Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  AC Immune SA    ACIU   CH0329023102

AC IMMUNE SA

(ACIU)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

AC Immune : Down 43%; Semorinemab Didn't Meet Endpoint in Early Alzheimer's Disease

share with twitter share with LinkedIn share with facebook
09/23/2020 | 01:16pm EDT

By Michael Dabaie

 

AC Immune SA shares fell 43% to $4.97 in afternoon trading.

The company said before the market open that a Phase 2 trial of semorinemab didn't meet the co-primary efficacy endpoint or two secondary endpoints for early Alzheimer's disease. Swiss-based clinical-stage biopharmaceutical company AC Immune said its partner, Roche Group's Genentech, informed the company of the top-line results of the trial, which showed the anti-Tau antibody semorinemab didn't meet its co-primary goal of reducing the decline on Clinical Dementia Rating-Sum of Boxes compared to a placebo.

The secondary endpoints of Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 and Alzheimer's Disease Cooperative Study Group--Activities of Daily Living Inventory also weren't met, AC Immune said.

The company said additional data analyses are ongoing and Genentech plans to present the results from the trial at an upcoming medical congress. The second Phase 2 study of semorinemab in patients with moderate Alzheimer's disease remains ongoing, the company said.

"This is clearly disappointing news for the company and for the Alzheimer's community given that Tau has been increasingly viewed as a promising target for treating AD," SVB Leerink said in a note.

"Our view on this stock has not changed -- ACIU is still a great way to get leverage to the AD space in a very diversified way through multiple assets, multiple target approaches and modalities, and multiple strong partners that pay for so much of the product development that AC Immune has a very long runway of cash," the SVB analyst note said. The firm maintained its Outperform rating on the stock

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 


Stocks mentioned in the article
ChangeLast1st jan.
AC IMMUNE SA 6.71% 4.77 Delayed Quote.-44.01%
ROCHE HOLDING AG -0.64% 297.25 Delayed Quote.-4.73%
share with twitter share with LinkedIn share with facebook
All news about AC IMMUNE SA
10/09Competitive EU Grant Supports Collaboration to Accelerate Development of AC I..
GL
09/23AC IMMUNE : Down 43%; Semorinemab Didn't Meet Endpoint in Early Alzheimer's Dise..
DJ
09/23Roche Alzheimer's drug fails, joining long list of trial flops
RE
09/23AC IMMUNE : Down; Semorinemab Didn't Meet Efficacy Endpoint in Early Alzheimer's..
DJ
09/23AC IMMUNE : Semorinemab Didn't Meet Co-Primary Efficacy Endpoint in Early Alzhei..
DJ
09/23AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semo..
GL
09/11AC Immune to Showcase Anti-Tau Portfolio at H.C. Wainwright 22nd Annual Globa..
GL
08/05AC Immune Reports Q2 2020 Financial Results and Provides Business Update
GL
08/03AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targetin..
GL
07/30AC Immune Wins Prestigious Award to Develop a “Game-Changing” Par..
GL
More news
Financials
Sales 2020 14,5 M 16,0 M 16,0 M
Net income 2020 -62,3 M -68,7 M -68,7 M
Net Debt 2020 - - -
P/E ratio 2020 -4,76x
Yield 2020 -
Capitalization 311 M 343 M 342 M
Capi. / Sales 2020 21,4x
Capi. / Sales 2021 6,87x
Nbr of Employees 124
Free-Float 53,0%
Chart AC IMMUNE SA
Duration : Period :
AC Immune SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AC IMMUNE SA
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 11,14 CHF
Last Close Price 4,05 CHF
Spread / Highest target 263%
Spread / Average Target 175%
Spread / Lowest Target 94,1%
EPS Revisions
Managers
NameTitle
Andrea Pfeifer Chief Executive Officer & Director
Douglas E. Williams Chairman
Jörg Hornstein Chief Financial Officer
Marie Kosco-Vilbois Chief Scientific Officer
Piergiorgio Donati Chief Technical Operations Officer
Sector and Competitors
1st jan.Capitalization (M$)
AC IMMUNE SA-47.54%321
LONZA GROUP AG62.00%47 011
SEAGEN INC.73.04%34 401
IQVIA HOLDINGS INC.9.54%32 445
CELLTRION, INC.31.22%28 807
MODERNA, INC.249.54%26 978